FDA Priorities under a Biden Administration

17 December 2020

By Dr Nicola Davies

The year 2020 has brought unprecedented scientific challenges for the US Food and Drug Administration as it joined the global battle against the COVID-19 pandemic. Despite the challenges faced, the FDA stands in a strong position, with robust scientific and regulatory processes in place to evaluate potential COVID-19 vaccines and drugs.

So, what will 2021 bring for the federal agency? Following his success in the 2020 US Presidential Election, former Vice President Joe Biden has begun his transition into the White House. With President-elect Biden due to take office on January 20, 2021, what changes can we expect within the FDA?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK